Ainnocence Inc., a leader in AI-driven biotech solutions, is proud to announce the launch of CellulaAI™, an innovative AI ...

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’Topline safety data of SB101 Phase 1 study expected ...

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic ...

Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple ...

阿柏西普是由再生元与拜耳共同研发的全球首个完全人源化的融合蛋白。虽然比雷珠单抗晚上市约5年，但阿柏西普卓越的疗法及亲民的价格，短时间内就奠定了其全球AMD领域的绝对优势地位。阿柏西普上市第一年销售额就达到了8.38亿美元；2022年，阿柏西普销售额为 ...

目前，全球已有雷珠单抗、阿柏西普、康柏西普和布西珠单抗、法瑞西单抗5款眼用抗VEGF药物获批上市。其中，雷珠单抗、康柏西普、阿柏西普和法瑞西单抗四款药物已经在中国获批上市。

2024 年 9 月 11 日，复旦大学生命科学学院王鹏飞团队联合香港大学微生物系朱轩团队于知名期刊 Emerging Microbes & Infections 发表题为“ Bispecific Antibodies Provide Broad Neutralization of Emerging Beta-Coronaviruses by Targeting ACE2 and Viral ...

These toxins provide new tools for precision cancer medicine, bringing us closer to the elusive “magic bullet.” In addition, ...

一年一度的世界肺癌大会（WCLC）是肺癌领域的国际学术盛会。备受全球瞩目的WCLC ...

近日，北京大学人民医院泌尿外科徐涛团队联合中国科学院深圳先进技术研究院和北京大学基础医学院，在Advanced Science在线发表题为“Novel CAR-T Cells Specifically Targeting SIA-CIgG ...